Saturday, March 3, 2012

Blockbuster Pills & Bitter Year 2012


Hi IP MADs,
The imminent arrival of the dreaded "patent cliff" has been haunting the pharmaceutical industry for years. With the patents of an unprecedented number of blockbuster brand drugs expiring in 2012, it will be a bitter year for patent owners.
Table: Top 10 Drugs Going To Be Off-Patent In 2012
Sr. No.
Patent expiring in 2012
Active Pharmaceutical Ingredient
Company
Use
2010 U.S. Sales
1
Plavix
Clopidrogrel
Bristol-myers squibb /
sanofi-aventis
Anti-platelet
$6,154,000,000
2
Seroquel
Quetiapine

Astrazeneca
Antipsychotic
$3,747,000,000
3
Singulair
Montelukast
Merck
Asthma
$3,224,000,000
4
Actos
Pioglitazone
Takeda
Type 2 diabetes
$3,351,000,000
5
Enbrel
Etanercept
Amgen
Arthritis
$3,304,000,000
6
Lexapro
Escitalopram
Forest
Antidepressant
$2,560,000,000
7
Diovan/HCT
Valsartan/ Hydrychlorothiazide
Novartis
Angiotensin II receptor Antagonist/ Thiazide Diuretic
$2,533,000,000


8
Tricor
Fenofibrate
Abbott
Hypercholesterolemia and Hypertriglyceridemia.
$1,345,000,000
9
Geodon
Ziprasidone
Pfizer
Atypical Antipsychotic
$1,281,000,000
10
Provigil
Modafinil
Cephalon
Analeptic
$1,133,000,000

References

No comments:

Post a Comment